Elias Jabbour, MD, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia that are moving the paradigm away from chemotherapy.
Elias Jabbour, MD, professor of medicine at The University of Texas MD Anderson Cancer Center, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia (ALL) that are moving the paradigm away from chemotherapy.
There has been a lot of evolution in this field, including the development of tyrosine kinase inhibitors (TKIs), monoclonal antibodies, bispecific T-cell engager (BiTE) antibodies, and CAR T cells, Jabbour says. For patients with Philadelphia chromosome-positive ALL, TKIs in combination with chemotherapy have shown great benefit in improving survival. Today, survival at 5 years is approaching 70%, Jabbour says.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More